Last reviewed · How we verify
Mepolizumab 100 milligrams
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system.
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).
At a glance
| Generic name | Mepolizumab 100 milligrams |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-5 antagonist monoclonal antibody |
| Target | IL-5 (Interleukin-5) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-5 is a key cytokine responsible for eosinophil development, recruitment, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in conditions characterized by eosinophilic inflammation, such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
Common side effects
- Headache
- Nasopharyngitis
- Back pain
- Fatigue
- Injection site reactions